Document text
Principal Investigator: ROBERT H CARNAHAN
Organization: VANDERBILT UNIVERSITY MEDICAL CENTER
Fiscal Year: 2024
Award: $5,228,898
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY - CORE D
The Vaccine and Therapeutics Technologies (VTT) Core will focus on developing a rapid pipeline for next-
generation vaccine and therapeutic antibody candidates. We will facilitate this by providing critical reagents,
consulting, and coordinating production and quality control of candidate molecules in myriad technology
platforms. This Core D will support all five Research Projects (RPs). The core group has five specific aims:
(Aim 1) Develop and produce recombinant virus-like particles (VLPs) as Picornavirus vaccine
candidates, supplied by Aleph Bio for Research Project 1 (RP1). (Aim 2) Design, production, purification,
modification, and quality control services for RNA lipid nanoparticles (RNA-LNPs) and rhesus adenoviral
(RhAd) vector vaccine platforms for RP1, RP3, and RP5. (Aim 3) Design, production, purification, modification,
and quality control services for circular RNA (circRNA) vaccine platforms for RP1, RP3, and RP5. (Aim 4)
Bolster the BP4 center network by offering the design and production of electroporation-delivered DNA-
encoded monoclonal antibodies for RP2, RP4, and RP5. (Aim 5) Provide access to design and broad
production capabilities for recombinant proteins and antibodies for all RPs.
The VTT Core will prioritize the utilization of vaccine and antibody candidate molecule generation
services by aligning with the goals of the BP4 consortium, which aims to develop and deploy next-generation
vaccine and therapeutic antibody candidates rapidly. This prioritization will occur through the core group
consulting all Research Projects (RPs) about each delivery technology's strengths, weaknesses, and overall
capabilities. This approach will help researchers make informed decisions about which technologies are most
suitable for their specific projects. The core leaders also will coordinate with the RP Proejct Leaders and
technology providers to ensure that the most promising candidates are produced and tested efficiently. The
core then will carry out production of the selected candidate molecules and perform extensive quality control
(QC) testing of the resulting reagents. This work will involve working closely with relevant working groups
across several organizations within the BP4 consortium. The VTT Core will ensure that the entire process,
from candidate molecule generation to QC, is carried out rapidly and with high quality standards. By focusing
on these objectives, the VTT Core will help prioritize candidate vaccines and antibodies in line with the
consortium's goals, ensuring that the most promising candidates are advanced efficiently through the
development pipeline.
Terms: <Ad vector><Adenoviral Vector><Adenovirus Vector><Antibodies><BBC1><BCL2-Interacting Killer Gene><BIK><BIK gene><BIP1><BP4><Bik/Nbk Gene><Bunyavirus><Clinical Treatment Moab><Communicable Diseases><Complex><DNA delivery><Dependence><Development><Electroporation><Engineering><Ensure><Evaluation><Family Picornaviridae><Generations><Goals><Grant><Health><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Investigators><Joints><Lead><MAb Therapeutics><Modality><Modification><Monoclonal Antibodies><NBK><Non-Polyadenylated RNA><Nucleic Acids><Orthobunyavirus><Pb element><Picornaviridae><Picornaviruses><Preparedness><Process><Production><Provider><Quality Control><R-Series Research Projects><R01 Mechanism><R01 Program><RNA><RNA Gene Products><Readiness><Reagent><Recombinant Antibody><Recombinant Proteins><Recombinants><Research><Research Grants><Research Personnel><Research Project Grants><Research Projects><Researchers><Rhesus><Ribonucleic Acid><Services><Social Support System><Support System><System><Technology><Test Result><Testing><Therapeutic><Therapeutic Monoclonal Antibodies><Therapeutic antibodies><Vaccine Antigen><Vaccines><Viral Vaccines><Viral Vector><Virus-like particle><Work><adeno vector><adenovector><animal efficacy><candidate selection><circular RNA><closed circular RNA><deliver DNA><deliver vaccines><delivery vector><delivery vehicle><design><designing><developmental><efficacy study><electroporative delivery><flexibility><flexible><gene electrotransfer><heavy metal Pb><heavy metal lead><lead candidate><lipid based nanoparticle><lipid nanoparticle><mAbs><manufacturing process><medical countermeasure><monoclonal Abs><monoclonal antibody drugs><new technology><new vaccines><next generation vaccines><novel technologies><novel vaccines><nucleic acid delivery><pandemic pathogen><recombinant virus><technology platform><technology system><therapeutic mAbs><vaccine antibodies><vaccine candidate><vaccine delivery><vaccine induced antibodies><vaccine platform><vaccine-induced antibodies><virus-like nanoparticles><viruslike particle><work group><working group>